Browse > Article
http://dx.doi.org/10.5483/BMBRep.2022.55.10.037

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells  

Moon, Byul (Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST))
Park, Mijin (Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST))
Cho, Seung-Hyun (Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST))
Kim, Kang Mo (Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine)
Seo, Haeng Ran (Advanced Biomedical Research Laboratory, Institut Pasteur Korea)
Kim, Jeong-Hoon (Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST))
Kim, Jung-Ae (Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST))
Publication Information
BMB Reports / v.55, no.10, 2022 , pp. 506-511 More about this Journal
Abstract
Advanced hepatocellular carcinoma (HCC) is among the most challenging cancers to overcome, and there is a need for better therapeutic strategies. Among the different cancer drugs that have been used in clinics, sorafenib is considered the standard first-line drug for advanced HCC. Here, to identify a chemical compound displaying a synergistic effect with sorafenib in HCC, we screened a focused chemical library and found that MG149, a histone acetyltransferase inhibitor targeting the MYST family, exhibited the most synergistic anticancer effect with sorafenib on HCC cells. The combination of sorafenib and MG149 exerted a synergistic anti-proliferation effect on HCC cells by inducing apoptotic cell death. We revealed that cotreatment with sorafenib and MG149 aggravated endoplasmic reticulum (ER) stress to promote the death of HCC cells rather than adaptive cell survival. In addition, combined treatment with sorafenib and MG149 significantly increased the intracellular levels of unfolded proteins and reactive oxygen species, which upregulated ER stress. Collectively, these results suggest that MG149 has the potential to improve the efficacy of sorafenib in advanced HCC via the upregulation of cytotoxic ER stress.
Keywords
Cell death; ER stress; Hepatocellular carcinoma; MG149; Sorafenib;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Shen D, Coleman J, Chan E et al (2011) Novel cell- and tissue-based assays for detecting misfolded and aggregated protein accumulation within aggresomes and inclusion bodies. Cell Biochem Biophys 60, 173-185   DOI
2 Wang C, Yu J, Huo L, Wang L, Feng W and Wang CC (2012) Human protein-disulfide isomerase is a redoxregulated Chaperone activated by oxidation of domain a'. J Biol Chem 287, 1139-1149   DOI
3 Coriat R, Nicco C, Chereau C et al (2012) Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 11, 2284-2293   DOI
4 Song Y, Kim JS, Kim SH et al (2018) Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma. J Exp Clin Cancer Res 37, 109   DOI
5 Corazzari M, Gagliardi M, Fimia GM and Piacentini M (2017) Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol 7, 78   DOI
6 Zou Y, Cong YS and Zhou J (2020) Implications of telomerase reverse transcriptase in tumor metastasis. BMB Rep 53, 458-465   DOI
7 Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390   DOI
8 Xia S, Pan Y, Liang Y, Xu J and Cai X (2020) The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51, 102610   DOI
9 Zhou T, Lv X, Guo X et al (2015) RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis. Oncol Rep 33, 3006-3014   DOI
10 Oyadomari S and Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11, 381-389   DOI
11 Novoa I, Zeng H, Harding HP and Ron D (2001) Feedback inhibition of the unfolded protein response by GADD34- mediated dephosphorylation of eIF2alpha. J Cell Biol 153, 1011-1022   DOI
12 Ogata M, Hino S, Saito A et al (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26, 9220-9231   DOI
13 Hetz C, Chevet E and Oakes SA (2015) Proteostasis control by the unfolded protein response. Nat Cell Biol 17, 829-838   DOI
14 Ma MKF, Lau EYT, Leung DHW et al (2017) Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Hepatol 67, 979-990   DOI
15 Lee S, Jeong Y, Roe JS, Huh H, Paik SH and Song J (2021) Mitochondrial dysfunction induced by callyspongiolide promotes autophagy-dependent cell death. BMB Rep 54, 227-232   DOI
16 Kaizuka T, Morishita H, Hama Y et al (2016) An autophagic flux probe that releases an internal control. Mol Cell 64, 835-849   DOI
17 Zhou B, Lu Q, Liu J, Fan L et al (2019) Melatonin increases the sensitivity of hepatocellular carcinoma to sorafenib through the PERK-ATF4-Beclin1 pathway. Int J Biol Sci 15, 1905-1920   DOI
18 Hetz C and Papa FR (2018) The unfolded protein response and cell fate control. Mol Cell 69, 169-181   DOI
19 Shimizu S, Takehara T, Hikita H et al (2012) Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 131, 548-557   DOI
20 Tanaka K, Yu HA, Yang S et al (2021) Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell 39, 1245-1261 e1246   DOI
21 Harris IS, Endress JE, Coloff JL et al (2019) Deubiquitinases maintain protein homeostasis and survival of cancer cells upon glutathione depletion. Cell Metab 29, 1166-1181 e1166   DOI
22 Green AS, Maciel TT, Hospital MA et al (2015) Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv 1, e1500221   DOI
23 Broux M, Prieto C, Demeyer S et al (2019) Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. Blood 134, 1323-1336
24 Niles AL, Moravec RA and Riss TL (2009) In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening. Curr Chem Genomics 3, 33-41   DOI
25 Sun Y, Jiang X, Chen S and Price BD (2006) Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett 580, 4353-4356   DOI
26 Yu H, Kim DJ, Choi HY et al (2021) Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines. BMC Cancer 21, 1049   DOI
27 Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay Method. Cancer Res 70, 440-446   DOI
28 Oslowski CM and Urano F (2011) Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol 490, 71-92   DOI
29 Lee CH, Han JH, Kim S et al (2020) Metformin ameliorates bile duct ligation-induced acute hepatic injury via regulation of ER stress. BMB Rep 53, 311-316   DOI
30 Lin A, Giuliano CJ, Palladino A et al (2019) Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 11, eaaw8412   DOI
31 Rahmani M, Davis EM, Crabtree TR et al (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27, 5499-5513   DOI
32 Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10, 25-34   DOI
33 Rimassa L and Worns MA (2020) Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver International 40, 1800-1811   DOI
34 Huang A, Yang XR, Chung WY, Dennison AR and Zhou J (2020) Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 5, 146   DOI
35 Won JK, Yu SJ, Hwang CY et al (2017) Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology 66, 855-868   DOI
36 Ghizzoni M, Wu J, Gao T et al (2012) 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. Eur J Med Chem 47, 337-344   DOI
37 Balasubramanyam K, Swaminathan V, Ranganathan A and Kundu TK (2003) Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278, 19134-19140   DOI
38 Kusakabe Y, Chiba T, Oshima M et al (2021) EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Sci Rep 11, 21396   DOI